Nasdaq smmt.

Based on analysts offering 12 month price targets for SMMT in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . Summit Therapeutics Inc (NASDAQ:SMMT) shares are down by almost 13% year to date bringing their 12-month return to over 85%. As of this writing, Summit Therapeutics shares are trading at around $3.70 with a 52-week range of $0.66 to $5.78, giving the company a market capitalization of more than $835 million. PDS …WebConference Call to be Held at 9:00am ET. MENLO PARK, Calif.--(BUSINESS WIRE)-- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to ...Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park, California, and we have additional offices in Oxford, UK.Summit Therapeutics Inc. (NASDAQ:SMMT) Short Interest Up 2,045.6% in December marketbeat.com - December 28 at 1:08 PM: Summit Therapeutics Inc.'s (NASDAQ:SMMT) CEO Robert Duggan is the most upbeat insider, and their holdings increased by 431% last week finance.yahoo.com - December 9 at 2:06 PM: marketbeat.com - December 9 at 10:28 AM

May 3, 2023 · Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park, California, and we have additional offices in Oxford, UK ...

Oxford, UK, and Cambridge, MA, US, 15 January 2020 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces that it has received notification that on 14 ...Oct 26, 2023 · MENLO PARK, Calif., October 26, 2023--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its third quarter 2023 financial results and ...

OXFORD, United Kingdom, Oct. 06, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular ...Summit Therapeutics (NASDAQ: SMMT ) announced during its Third Quarter 2023 Earnings and Update Call that it has started enrolling for the second Phase III clinical trial for ivonescimab, a potential treatment for non-small cell lung cancer. The company also introduced its new Chief Operating Officer, Manmeet Soni, who has made a $5 million …WebNov 18, 2023 · Summit Therapeutics Inc (NASDAQ:SMMT) trade information. Upright in the green during last session for gaining 3.76%, in the last five days SMMT remained trading in the green while hitting it’s week-highest on Wednesday, 11/15/23 when the stock touched $1.93 price level, adding 5.85% to its value on the day. Based on analysts offering 12 month price targets for SMMT in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .

View live Summit Therapeutics Inc. chart to track its stock's price action. Find market predictions, SMMT financials and market news.

Find the latest press releases from Summit Therapeutics Inc. Common Stock (SMMT) at Nasdaq.com.

26 de abr. de 2016 ... ... (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and ...Webull offers Summit Therapeutics Inc stock information, including NASDAQ: SMMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SMMT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for …WebLihat chart Summit Therapeutics Inc. live untuk melacak pergerakan harga sahamnya. Temukan prediksi pasar, berita finansial dan pasar dari SMMT.Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park, California, and we have additional offices in Oxford, UK.Shares of Summit Therapeutics Inc. (NASDAQ:SMMT – Get Free Report) were down 3.9% on Friday .The company traded as low as $1.94 and last traded at …Summit Therapeutics Inc. (NASDAQ:SMMT) has the sixth position on our list of the ten best penny stocks to buy in September. It is a Cambridge, Massachusetts-based clinical-stage drug discovery and ...Web

Follow. Cambridge, Massachusetts, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Dr. Urte Gayko, PhD, has been appointed to our Board of Directors ...Nov 7, 2023 · Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park, California, and we have additional offices in Oxford, UK. Nasdaq | SMMT U.S.: Nasdaq Summit Therapeutics Inc. Watch NEW Set a price target alert Premarket Last Updated: Nov 27, 2023 6:38 a.m. EST Delayed quote $ 2.0600 0.06 …Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park, California, and we have additional offices in Oxford, ...Mar 24, 2021 · Cambridge, MA, March 26, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that the Company’s Board of Directors has approved a rights offering available to all holders of record of ...

Dec 4, 2023 · TG Therapeutics Inc (NASDAQ:TGTX)’s Major holders. Insiders own 8.59% of the company shares, while shares held by institutions stand at 64.76% with a share float percentage of 70.85%. Investors are also buoyed by the number of investors in a company, with TG Therapeutics Inc having a total of 282 institutions that hold shares in the company. Summit Therapeutics Inc (NASDAQ:SMMT)’s traded shares stood at 0.38 million during the last session, with the company’s beta value hitting -1.00. At the close of trading, the stock’s price was $2.00, to imply an increase of 2.56% or $0.05 in intraday trading. The SMMT share’s 52-week high ...

OXFORD, United Kingdom, Sept. 27, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular ...Cambridge, MA, November 23, 2020 – Summit Therapeutics Inc. (NASDAQ: SMMT) announces that Dr. Mahkam “Maky” Zanganeh, DDS, MBA, has been appointed as Chief Operating Officer, effective ...Create your Watchlist to save your favorite quotes on Nasdaq.com. Log in or create a free account to get started. Outsmart the market with Smart Portfolio analytical tools powered …Dec 4, 2023 · Avenue Therapeutics Inc (NASDAQ:ATXI)’s Major holders. Insiders own 18.50% of the company shares, while shares held by institutions stand at 9.14% with a share float percentage of 11.21%. Investors are also buoyed by the number of investors in a company, with Avenue Therapeutics Inc having a total of 17 institutions that hold shares in the ... Cambridge, Massachusetts-based biotech Summit Therapeutics (NASDAQ:SMMT) jumped ~38% pre-market Tuesday after announcing a collaboration and license agreement with Hong Kong-listed biopharma Akeso ...Shares of Summit Therapeutics Inc. (NASDAQ:SMMT – Get Free Report) were down 3.9% on Friday .The company traded as low as $1.94 and last traded at …

Cambridge, MA, July 12, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) is today displaying three preeminent ePosters at the prestigious 31st ...Web

The public float for SMMT is 111.77M and currently, short sellers hold a 8.48% ratio of that float. The average trading volume of SMMT on November 16, 2023 was 972.70K shares. SMMT) stock’s latest price update. The stock of Summit Therapeutics Inc (NASDAQ: SMMT) has increased by 0.51 when compared to last closing price of 1.97.

CEO. Website. 2003. 77. Bob Duggan. https://www.summittxinc.com. Summit Therapeutics Inc., a biopharmaceutical company, research and develops primarily oncology therapies in the United States, and the United Kingdom. The company’s product pipeline includes SMT-738, a novel class of precision antibiotics for treatment which is in preclinical ...Summit Therapeutics Inc. (NASDAQ:SMMT) Q3 2023 Earnings Call Transcript November 7, 2023 Operator: Good morning, and welcome to the Summit Therapeutics Third Quarter 2023 Earnings and Update Call.As part of this collaboration deal, Summit Therapeutics paid $500 million upfront (financed via a rights offering) and could be on the hook for another $4.5 billion in future milestone payouts ($1 ...TG Therapeutics Inc (NASDAQ:TGTX)’s Major holders. Insiders own 8.59% of the company shares, while shares held by institutions stand at 64.76% with a share float percentage of 70.85%. Investors are also buoyed by the number of investors in a company, with TG Therapeutics Inc having a total of 282 institutions that hold shares in the company.Interactive Chart for Summit Therapeutics Inc. (SMMT), analyze all the data with a huge range of indicators.OXFORD, UK, Jan. 21, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (LSE:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ...Oxford, UK, and Cambridge, MA, US, 17 December 2018 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, today announces that Erik Ostrowski will ...Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park, California, and we have additional offices in Oxford, UK ...WebDec 1, 2023 · During the last session, Summit Therapeutics Inc (NASDAQ:SMMT)’s traded shares were 1.99 million, with the beta value of the company hitting -1.00. At the end of the trading day, the stock’s price was $2.03, reflecting an intraday gain of 4.10% or $0.08. The 52-week high for the SMMT share is $5 ... Cambridge, Massachusetts-based biotech Summit Therapeutics (NASDAQ:SMMT) jumped ~38% pre-market Tuesday after announcing a collaboration and license agreement with Hong Kong-listed biopharma Akeso ...

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the first United States-based patient has been enrolled in the Phase III HARMONi study. HARMONi is a Phase III multiregional, randomized, double-blinded study. The study will evaluate the efficacy and safety of ivonescimab combined …Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2023 Earnings Call Transcript May 11, 2023 Operator: Good morning, and welcome to the Summit Therapeutics First Quarter 2023 Earnings and Update Call.Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park, California, and we have additional offices in Oxford, UK ...WebBy way of example, Summit Therapeutics (NASDAQ:SMMT) has seen its share price rise 106% over the last year, delighting many shareholders. Having said that, unprofitable companies are risky because ...Instagram:https://instagram. peoloton stockrng stocksbest account to day tradedental insurance plans georgia Summit Therapeutics Inc. Common Stock (SMMT) Analyst Research | Nasdaq in the last 3 months. The average price target is Sign in to your SmartPortfolio to see more analyst …Oxford, UK, and Cambridge, MA, US, 25 February 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, published preclinical data on SMT-571, a ... brokerage firms that accept penny stocksmicrosoft stock price prediction Summit Therapeutics (NASDAQ: SMMT) does not pay a dividend. Does Summit Therapeutics have sufficient earnings to cover their dividend? brite co reviews BABA. 73.60. -1.71%. 19.59M. New. View today's Summit Therapeutics PLC stock price and latest SMMT news and analysis. Create real-time notifications to follow any changes in the live stock price.WebSummit Therapeutics Inc. (NASDAQ:SMMT) has the sixth position on our list of the ten best penny stocks to buy in September. It is a Cambridge, Massachusetts-based clinical-stage drug discovery and ...Web